Sutro Biopharma (STRO) PT Raised to $16 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts STRO Hot Sheet
Price: $9.51 --0%
Rating Summary:
14 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 20 | New: 12
Rating Summary:
14 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 20 | New: 12
Join SI Premium – FREE
Piper Sandler analyst Edward Tenthoff raised the price target on Sutro Biopharma (NASDAQ: STRO) to $16.00 (from $14.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Sutro Biopharma to Participate in Upcoming Investor Conferences
- Muyuan Foods Co Ltd (002714:CH) PT Raised to RMB69 at Macquarie
- LG Household & Health Care Ltd (0519000:KS) (LGHHF) PT Lowered to KRW255,000 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
